Our Organoid & Immune Cell Co-culture Service offers a cutting-edge platform to capture critical tumor–immune interactions using patient-derived tumor organoids and diverse immune cell types by combining organoid models with immune cells, we provide valuable insights into immune activation, tumor immune evasion, and therapeutic efficacy. This customizable co-culture model supports diverse research applications, including targeted drug testing, immune modulation studies, and the optimization of immunotherapies. By preserving patient-specific tumor heterogeneity, our platform accelerates the development of more effective and personalized immunotherapeutic strategies.
Organoid & Immune Cell Co-culture ModelOgCelix provides tumor organoid-immune cell co-culture services based on patient-derived organoids (PDOs). This service utilizes autologous immune cells (such as PBMCs, TILs) and co-cultured with tumor organoid model to simulate the immune recognition and cytotoxicity. The service supports co-culture with various immune cell types, including PBMCs, T cells, CAR-T cells, NK cells, and can be customized based on the patient-specific pathological and molecular features, offering a precise platform for immune therapy evaluation and the study of tumor immune escape mechanisms.
Organoids Bi Specific Antibody AssaysUsing the co-culture system established with human tumor organoids, autologous PBMCs and TILs, we provide a a robust platform for evaluating bispecific antibodies with high individual diversity. The systems preserves tumor heterogeneity, reflects the patient-specific antigen expression, and supports functional interaction with T cells, thereby reducing risks associated with in vivo studies and guiding candidate antibody optimization.
Adoptive T Cell Therapy AnalysisOrganoids are co-cultured with CAR-T, Neo-T, or CAR-NK effector cells to evaluate tumor-killing potency, immune activation, cytokine responses, and persistence. This preclinical assay provides human-relevant pharmacodynamic data and mechanistic insights, enabling characterization of therapeutic efficacy, comparison of engineered cell products, and optimization of adoptive T cell therapy strategies for translational development.
Organoid & Immune Cell Co-culture Service content includes but is not limited to:
| Organoid & Immune Cell Co-culture Service | ||
|---|---|---|
| Organoid & Immune Cell Co-culture Model | Organoid + CAR-T cells | |
| Organoid + Tumor-Infiltrating Lymphocytes (TILs) | ||
| Organoid + Natural Killer (NK) Cells | ||
| Organoid + Dendritic Cells (DCs) | ||
| Organoid + Tumor-Associated Macrophages (TAMs) | ||
| Organoid + B Cells / Plasma Cells | ||
| Organoids Bi Specific Antibody Assays | Inquiring about Service Details | |
| Adoptive T Cell Therapy Analysis | Inquiring about Service Details | |
Key Advantages:
Diverse Immune Cells: Compatible with PBMCs, T cells, CAR-T, NK cells, dendritic cells, macrophages, and B cells.
Multi-Parameter Evaluation: Enables flow cytometry, live-cell imaging, cytotoxicity assays, and cytokine profiling.
Flexible and Customizable: Supports varied tumor types, immune cell sources, and co-culture configurations.